Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11142722 | 0.83 | — | — | |
| SCHEMBL8978099 | 0.75 | GAA (0.70) | GAAALDH1A1MEN1KMT2AHTT | |
| SCHEMBL3644435 | 0.75 | CA1 (0.46) | GAA | |
| SCHEMBL680281 | 0.75 | LMNA (0.39) | GAAALDH1A1MEN1KMT2AHTT | |
| SCHEMBL3634814 | 0.74 | GAA (0.85) | GAAALDH1A1MEN1KMT2AHTT | |
| SCHEMBL3630393 | 0.74 | GAA (0.85) | GAAALDH1A1MEN1KMT2AHTT | |
| SCHEMBL15283000 | 0.74 | GAA (0.95) | GAAALDH1A1MEN1KMT2AHTT | |
| SCHEMBL11055841 | 0.73 | GAA (0.67) | GAAALDH1A1MEN1KMT2AHTT | |
| SCHEMBL20329944 | 0.73 | — | — | |
| SCHEMBL14263102 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119390-A1 | TRICYCLIC COMPOUNDS | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2022-04-21 | — | — | US | disclosed |
| US-20210179617-A1 | TRICYCLIC COMPOUNDS | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2021-06-17 | — | — | US | disclosed |
| US-20160311817-A1 | HETEROARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2016-10-27 | — | — | US | disclosed |
| US-9115101-B2 | Aryl sultam derivatives as RORc modulators | GENENTECH, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150197529-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| US-20140031330-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH INC (US) | 2014-01-30 | — | — | US | disclosed |
| US-8580786-B2 | Triazine derivatives and their therapeutical applications | NANT HOLDINGS IP, LLC (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130023497-A1 | Triazine Derivatives and their Therapeutical Applications | NANTBIO, INC. | 2013-01-24 | — | — | US | disclosed |
| US-20120238576-A1 | Triazine Derivatives and their Therapeutical Applications | CALIFORNIA CAPITAL EQUITY, LLC (CA) | 2012-09-20 | — | — | US | disclosed |
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-12 | — | — | US | disclosed |
| US-20110150763-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | ABRAXIS BIOSCIENCE, LLC (US) | 2011-06-23 | — | — | US | disclosed |
| US-7858782-B2 | Triazine derivatives and their therapeutical applications | ABRAXIS BIOSCIENCE, LLC (US) | 2010-12-28 | — | — | US | disclosed |
| US-7851467-B2 | Carbamate compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-20080176853-A1 | e.g. N-(2-chloro-6-methylphenyl)-3-ethoxyacrylamide; protein (tyrosine and serine/threonine) kinase inhibitor; variety of conditions and diseases; antiproliferative, anticarcinogenic, antiinflammatory, antiallergenic agent; autoimmune and neurodegenerative disorders | ABRAXIS BIOSCIENCE, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080090811-A1 | Carbamate compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-04-17 | — | — | US | disclosed |
| US-7329752-B2 | Carbamate compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-20070275964-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER, INC. | 2007-11-29 | — | — | US | disclosed |
| US-7268133-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. PATENT DEPARTMENT (US) | 2007-09-11 | — | — | US | disclosed |
| US-20070117796-A1 | Carbamate compounds as 5-HT4 receptor agonists | THERAVANCE, INC. | 2007-05-24 | — | — | US | disclosed |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197529-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | GAA 2964/4885ALDH1A1 427/4885MEN1 4726/4885 |
| US-20070117796-A1 | Carbamate compounds as 5-HT4 receptor agonists | HTR4, HTR1A, HTR2B | GAA 4253/4885ALDH1A1 2518/4885MEN1 1445/4885 |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | GAA 3224/4885ALDH1A1 1683/4885MEN1 4394/4885 |
| US-20130023497-A1 | Triazine Derivatives and their Therapeutical Applications | IL5, IKZF3, CYP11B2 | GAA 691/4885ALDH1A1 360/4885MEN1 4203/4885 |
| US-20080090811-A1 | Carbamate compounds as 5-HT4 receptor agonists | HTR4, HTR1A, HTR2B | GAA 4253/4885ALDH1A1 2518/4885MEN1 1445/4885 |
| US-20210179617-A1 | TRICYCLIC COMPOUNDS | BRD4, BET1, BRD3 | GAA 744/4885ALDH1A1 3589/4885MEN1 2550/4885 |
| US-20160311817-A1 | HETEROARYL SULTAM DERIVATIVES AS RORc MODULATORS | RORC, RORA, RORB | GAA 2968/4885ALDH1A1 994/4885MEN1 4566/4885 |
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | STK25, STK35, SGK2 | GAA 3176/4885ALDH1A1 3351/4885MEN1 4391/4885 |
| US-20140031330-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | GAA 2970/4885ALDH1A1 451/4885MEN1 4705/4885 |
| US-20120238576-A1 | Triazine Derivatives and their Therapeutical Applications | SLC10A1, GLS, SLC10A2 | GAA 688/4885ALDH1A1 494/4885MEN1 3798/4885 |
| US-20110150763-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | BAZ2A, CAMKK2, BAZ1A | GAA 1495/4885ALDH1A1 3429/4885MEN1 4476/4885 |
| US-20080176853-A1 | e.g. N-(2-chloro-6-methylphenyl)-3-ethoxyacrylamide; protein (tyrosine and serine/threonine) kinase inhibitor; variety of conditions and diseases; antiproliferative, anticarcinogenic, antiinflammatory, antiallergenic agent; autoimmune and neurodegenerative disorders | MAP3K15, DSTYK, STK25 | GAA 1774/4885ALDH1A1 4099/4885MEN1 2868/4885 |
| US-20070275964-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, GPR18 | GAA 3111/4885ALDH1A1 1926/4885MEN1 4519/4885 |
| US-20220119390-A1 | TRICYCLIC COMPOUNDS | BRD4, BET1, BRD3 | GAA 744/4885ALDH1A1 3589/4885MEN1 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.